ALK and cancer: Consequently, the results from the post-first line progressed study cohort help provide an overarching view of potentially better survival outcomes in patients that were administered two or more ALK TKIs throughout their cancer journey but should not be used to compare the effectiveness of specific sequential ALK TKI regimens, as the sequencing and timing of specific therapies was not accounted for in this cohort.